New hope for bladder cancer patients ineligible for chemo
NCT ID NCT04610671
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 23 times
Summary
This early-phase study tested a combination of two drugs—CG0070 (given directly into the bladder) and nivolumab (given through a vein)—in 21 people with muscle-invasive bladder cancer who could not receive the standard chemotherapy drug cisplatin. The main goal was to check safety and side effects, while also looking at how the treatment affected the tumor and immune system. The study is complete, and results help guide future research for this hard-to-treat group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.